Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

New Target Fights Ferroptosis- and Radio-Resistance in Lung Cancers

Oncotarget

November 2, 2022
Researchers published a research perspective about a recent study that uncovered FSP1 as a novel target gene that mediates ferroptosis resistance and radioresistance in lung cancer cells. continue reading »

Oncotarget is Again on MEDLINE

News

October 27, 2022
PRESS RELEASE: On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed. continue reading »

Oncotarget | Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models

News

October 25, 2022
PRESS RELEASE: On October 19, 2022, a new research paper was published in Oncotarget, entitled, “Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models.” continue reading »

Oncotarget | Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer

News

October 20, 2022
PRESS RELEASE: On October 19, 2022, a new research paper was published in Oncotarget, entitled, “Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.” continue reading »

Synergy of HDACi, PARPi and Chemotherapeutics Against Blood Cancer

Oncotarget

October 18, 2022
Researchers investigated the efficacy of HDAC inhibitors in combination with PARP inhibitors and chemotherapeutic drugs in multiple blood cancer cell lines. continue reading »